Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 3
2015 1
2016 4
2017 4
2018 1
2019 1
2020 5
2021 7
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Chen EX, et al. Among authors: tehfe m. Clin Colorectal Cancer. 2024 Apr 1:S1533-0028(24)00024-0. doi: 10.1016/j.clcc.2024.03.002. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38653648
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. Janjigian YY, et al. Among authors: tehfe m. J Clin Oncol. 2024 Feb 21:JCO2301601. doi: 10.1200/JCO.23.01601. Online ahead of print. J Clin Oncol. 2024. PMID: 38382001
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Hoffert C, Srivastava A, Schab A, Alcindor T, Langleben A, Sideris L, Abdelsalam M, Tehfe M, Couture F, Batist G, Kavan P. Gambaro K, et al. Among authors: tehfe m. Int J Mol Sci. 2023 Dec 19;25(1):43. doi: 10.3390/ijms25010043. Int J Mol Sci. 2023. PMID: 38203214 Free PMC article. Clinical Trial.
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F, Routy B, Nassabein R, Belkaid W, Tran-Thanh D, Malo J, Tonneau M, Ouarzadi OE, Florescu M, Tehfe M, Blais N. Proulx-Rocray F, et al. Among authors: tehfe m. Cancer Treat Res Commun. 2023;37:100767. doi: 10.1016/j.ctarc.2023.100767. Epub 2023 Oct 10. Cancer Treat Res Commun. 2023. PMID: 37832364 Free article.
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Wong P, Masucci L, Florescu M, Plourde ME, Panet-Raymond V, Pavic M, Owen S, Masson-Coté L, Ménard C, Routy B, Tehfe M, Nelson K, Guilbert F, Boucher O, Keshavarzi S, Blais N, Roberge D. Wong P, et al. Among authors: tehfe m. Neurooncol Adv. 2023 Mar 1;5(1):vdad018. doi: 10.1093/noajnl/vdad018. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37025758 Free PMC article.
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.
Ma LX, Wang Y, Espin-Garcia O, Allen MJ, Jang GH, Zhang A, Dodd A, Ramotar S, Hutchinson S, Tehfe M, Ramjeesingh R, Biagi J, Wilson JM, Notta F, Fischer SE, Zogopoulos G, Gallinger S, Grant RC, Khokha R, Chan N, Grünwald BT, Knox JJ, O'Kane GM. Ma LX, et al. Among authors: tehfe m. Br J Cancer. 2023 May;128(10):1916-1921. doi: 10.1038/s41416-023-02214-0. Epub 2023 Mar 16. Br J Cancer. 2023. PMID: 36927977 Free PMC article.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, Denroche RE, Dodd A, Ramotar S, Hutchinson S, Tehfe M, Ramjeesingh R, Biagi J, Lam B, Wilson J, Fischer SE, Zogopoulos G, Notta F, Gallinger S, Grant RC, Knox JJ, O'Kane GM. Perera S, et al. Among authors: tehfe m. Clin Cancer Res. 2022 Dec 1;28(23):5115-5120. doi: 10.1158/1078-0432.CCR-22-2576. Clin Cancer Res. 2022. PMID: 36222851
39 results